Humira, one of the top-selling drugs in the US, is about to see a slew of competition with seven adalimumab biosimilars approved and set to launch in 2023. We’ll explore how we can expect the market to react and how factors such as launch timing, interchangeability, and contracting will shape the immunology landscape.
- How have payers changed their strategy in anticipation of the availability of adalimumab biosimilars next year?
- What is the payer perception of the adalimumab biosimilars and of the staggered launches of these products throughout 2023?
- Between Humira and the biosimilars, how many do payers anticipate they will cover and what factors are going to inform these decisions?
- What are the considerations for patients who are currently being prescribed Humira?